A history of prostate cancer treatment

[1]  S. Liao,et al.  Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 alpha-dihydrotestosterone in rat ventral prostate. , 1974, Endocrinology.

[2]  J. Knowelden,et al.  Cancer Epidemiology and Prevention , 1976, British Journal of Cancer.

[3]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[4]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[5]  B. Given,et al.  Compliance among patients with cancer. , 1989, Oncology nursing forum.

[6]  J. Palmer,et al.  The Works of John Hunter, F.R.S.; with Notes , 1837, The British and foreign medical review.

[7]  J. W. White.  II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1893, Annals of surgery.

[8]  L. Wallentin,et al.  The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. , 1982, Scandinavian journal of urology and nephrology.

[9]  R. Sylvester,et al.  Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. , 1986, The Journal of urology.

[10]  P. Wingo,et al.  Cancer statistics by race and ethnicity , 1998, CA: a cancer journal for clinicians.

[11]  J. N. Morris.  Controlled trial of soyabean oil in myocardial infarction. , 1968 .

[12]  N. Bruchovsky,et al.  The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. , 1968, The Journal of biological chemistry.

[13]  K. Tew,et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. A. del Regato,et al.  Radiotherapy in the conservative treatment of operable and locally inoperable carcinoma of the prostate. , 1967, Radiology.

[15]  J. A. D. Regato.  Radiotherapy in the Conservative Treatment of Operable and Locally Inoperable Carcinoma of the Prostate , 1967 .

[16]  S. Steckel.  Predicting, measuring, implementing and following up on patient compliance. , 1982, The Nursing clinics of North America.

[17]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Murphy,et al.  Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. , 1975, The Journal of urology.

[19]  E. Ruoslahti,et al.  An address system in the vasculature of normal tissues and tumors. , 2000, Annual review of immunology.

[20]  N. Slack,et al.  Response criteria for the prostate of the USA national prostatic cancer project , 1980, The Prostate.

[21]  B. Trock,et al.  Factors associated with repeat adherence to breast cancer screening. , 1990, Preventive medicine.

[22]  S. Machtens.  [Retropubic implantation of iodine 125 in the treatment of prostatic cancer]. , 2003, Aktuelle Urologie.

[23]  Robert A. Moore,et al.  A Histological Study of the Effect of the Sex Hormones on the Human Prostate1 , 1938 .

[24]  Elder Js,et al.  Ongoing phase II & III studies of the USA National Prostatic Cancer Project. , 1985 .

[25]  R. Elashoff,et al.  A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. , 1990, Archives of general psychiatry.

[26]  S. Litwin,et al.  Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Ortaldo,et al.  Natural killer cells: their roles in defenses against disease. , 1981, Science.

[28]  G. Murphy,et al.  A prostate antigen in sera of prostatic cancer patients. , 1980, Cancer research.

[29]  Suzanne M. Miller,et al.  Telephone counseling improves adherence to colposcopy among lower-income minority women. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Small,et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Lytton.  Prostate cancer: a brief history and the discovery of hormonal ablation treatment. , 2001, The Journal of urology.

[32]  F. Keefe,et al.  Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. , 1998, Journal of consulting and clinical psychology.

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  C. Logothetis,et al.  Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Nicholas,et al.  The Intranuclear Binding of Testosterone and Sa-AndrostanX’@-ol-5one by Rat Prostate* , 2003 .

[36]  A. Kastin,et al.  Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. , 1971, Fertility and sterility.

[37]  C. Huggins,et al.  QUANTITATIVE STUDIES OF PROSTATIC SECRETION , 1939, The Journal of experimental medicine.

[38]  D. Spiegel.  Healing words: emotional expression and disease outcome. , 1999, JAMA.

[39]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[40]  D Ackman,et al.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[42]  A. Schally,et al.  Peptide analogs in the therapy of prostate cancer , 2000, The Prostate.

[43]  J. Drago,et al.  Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. , 1976, The Journal of urology.

[44]  S. Liao,et al.  Selective Retention of Dihydrotestosterone by Prostatic Nuclei , 1968, Nature.

[45]  R. Castellino,et al.  External beam radiation therapy of primary carcinoma of the prostate , 1975, Cancer.

[46]  F. Labrie,et al.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. , 1982, Clinical and investigative medicine. Medecine clinique et experimentale.

[47]  H. Holm,et al.  Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. , 1983, The Journal of urology.

[48]  J. Pinski,et al.  Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. , 2001, Cancer research.

[49]  W. Mainwaring.  A soluble androgen receptor in the cytoplasm of rat prostate. , 1969, The Journal of endocrinology.

[50]  S. Christensen,et al.  Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. , 2001, Journal of medicinal chemistry.

[51]  W. Whitmore,et al.  Retropubic implantation to iodine 125 in the treatment of prostatic cancer. , 1972, The Journal of urology.

[52]  J. Isaacs,et al.  Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. , 1998, The cancer journal from Scientific American.

[53]  R. Wittes,et al.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Krischer,et al.  Effects of health insurance and race on colorectal cancer treatments and outcomes. , 2000, American journal of public health.

[55]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[56]  S. Loening,et al.  Chemotherapy Programs of the National Prostatic Cancer Project (NPCP) , 1980, Cancer.

[57]  P. J. Clark,et al.  QUANTITATIVE STUDIES OF PROSTATIC SECRETION : II. THE EFFECT OF CASTRATION AND OF ESTROGEN INJECTION ON THE NORMAL AND ON THE HYPERPLASTIC PROSTATE GLANDS OF DOGS. , 1940 .

[58]  E. Sproul,et al.  Significance of Increased Phosphatase Activity of Bone at the Site of Osteoplastic Metastases Secondary to Carcinoma of the Prostate Gland , 1936 .

[59]  F. A. Dorr,et al.  Adjuvant therapy for breast cancer patients with negative lymph nodes. , 1986, NCI monographs : a publication of the National Cancer Institute.

[60]  F W GEORGE,et al.  COBALT-60 TELECURIETHERAPY IN THE DEFINITIVE TREATMENT OF CARCINOMA OF THE PROSTATE: A PRELIMINARY REPORT. , 1965, The Journal of urology.

[61]  M. Carducci,et al.  Complete androgen blockade for prostate cancer: what went wrong? , 2000, The Journal of urology.

[62]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[63]  H. Ragde,et al.  Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration. , 1988, Urology.

[64]  K. Pienta,et al.  Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  C. Huggins,et al.  QUANTITATIVE STUDIES OF PROSTATIC SECRETION : I. CHARACTERISTICS OF THE NORMAL SECRETION; THE INFLUENCE OF THYROID, SUPRARENAL, AND TESTIS EXTIRPATION AND ANDROGEN SUBSTITUTION ON THE PROSTATIC OUTPUT , 1939 .

[66]  D. Spiegel,et al.  Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma , 1997, Cancer.

[67]  C. Huggins,et al.  The Effect of Castration on Benign Hypertrophy of the Prostate in Man11This investigation was supported by a grant from the Committee on Research in Problems of Sex of the National Research Council. , 1940 .

[68]  W. von Rechenberg,et al.  Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. , 1978, Fertility and sterility.

[69]  H. Scher,et al.  Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. , 1999, Journal of the National Cancer Institute.

[70]  D. Stevens,et al.  Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.

[71]  F. Labrie,et al.  Combined long‐term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat , 1982, The Prostate.

[72]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[73]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[74]  A. Gutman,et al.  AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND. , 1938, The Journal of clinical investigation.

[75]  T. Millin,et al.  Retropubic prostatectomy: A new extravesical technique report on 20 cases , 2002 .

[76]  M. Lippman,et al.  Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Michael H. Antoni,et al.  Cognitive-Behavioral Stress Management Reduces Serum Cortisol By Enhancing Benefit Finding Among Women Being Treated for Early Stage Breast Cancer , 2000, Psychosomatic medicine.

[79]  Herbert Lepor,et al.  Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations , 1983, The Prostate.

[80]  T. Whiteside,et al.  The role of natural killer cells in immune surveillance of cancer. , 1995, Current opinion in immunology.

[81]  H. Kraemer,et al.  Diurnal cortisol rhythm as a predictor of breast cancer survival. , 2000, Journal of the National Cancer Institute.

[82]  R W Veltri,et al.  Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  G. Murphy,et al.  Use of human prostate-specific antigen in monitoring prostate cancer. , 1981, Cancer research.

[84]  H. Kaplan,et al.  LINEAR ACCELERATOR SUPERVOLTAGE RADIOTHERAPY. VII. CARCINOMA OF THE PROSTATE. , 1965, Radiology.

[85]  R Denis,et al.  [Survival of patients with cancer of the prostate]. , 1972, Journal d'urologie et de nephrologie.

[86]  R. Yirmiya,et al.  Stress increases metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system , 1991, Brain, Behavior, and Immunity.

[87]  P. Goodwin,et al.  The rationale and foundations of group psychotherapy for women with metastatic breast cancer. , 1998, International journal of group psychotherapy.

[88]  Jerome Seidenfeld,et al.  Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer , 2000, Annals of Internal Medicine.

[89]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[90]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[91]  H. Young.  THE USE OF RADIUM IN CANCER OF THE PROSTATE AND BLADDER: A PRESENTATION OF NEW INSTRUMENTS AND NEW METHODS OF USE , 1917 .

[92]  G. Kennealey,et al.  Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. , 1995, Urology.

[93]  W. Butler,et al.  Modern prostate brachytherapy. , 2000, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[94]  C. L. Deming,et al.  Further Studies in the Endocrinological Relationships of Prostatic Hypertrophy: The Effect of Castration on the Sub-Urethral Glands in the Posterior Urethra of the Rat1 , 1935 .

[95]  R. Herberman,et al.  Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. , 1985, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[96]  A. Schally,et al.  Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats. , 1979, Fertility and sterility.

[97]  C. Huggins,et al.  Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. , 1945, Annals of surgery.

[98]  Leuprolide versus diethylstilbestrol for metastatic prostate cancer. , 1984, The New England journal of medicine.

[99]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[100]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.